Physician profile
Aaron Peinado
NPI 1083486823
$2,229.79
in general payments reported to CMS, 2019-2025
25 companies · $1,385 in 2025
The $1,385 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $844 · 2025: $1,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,229.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $452.44 | 2024-2025 | Zenpep, Vowst |
| Astrazeneca Pharmaceuticals LP | $241.02 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $224.98 | 2024-2025 | |
| Novo Nordisk INC | $171.82 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $148.68 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Daiichi Sankyo INC. | $127.99 | 2024-2025 | Injectafer |
| Abbvie INC. | $117.35 | 2024-2025 | |
| Biosense Webster, INC. | $103.55 | 2025 | Qdot Micro |
| Astellas Pharma US INC | $82.45 | 2024-2025 | Veozah |
| Abiomed | $74.24 | 2024-2025 | Impella |
| Otsuka America Pharmaceutical, INC. | $64.77 | 2024-2025 | Rexulti |
| Antares Pharma, INC. | $62.60 | 2024 | Xyosted |
| Vertex Pharmaceuticals Incorporated | $50.33 | 2025 | |
| Exact Sciences Corporation | $41.41 | 2024-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $35.32 | 2025 | Gemtesa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.17 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $29.38 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $25.91 | 2025 | Capvaxive, Gardasil 9 |
| Phathom Pharmaceuticals, INC. | $25.19 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $21.14 | 2025 | Trintellix |
| Corcept Therapeutics | $21.10 | 2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.36 | 2025 | Xifaxan |
| Tolmar, INC. | $18.95 | 2025 | Jatenzo |
| Bayer Healthcare Pharmaceuticals INC. | $17.34 | 2024 | |
| Currax Pharmaceuticals LLC | $17.30 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Peinado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.